Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Computational Analysis of SOD1-G93A Mouse Muscle Biomarkers for Comprehensive Assessment of ALS Progression

  • Gómez-Gálvez, Pedro
  • Navarro, Victoria
  • Castro, Ana M.
  • Paradas, Carmen
  • Escudero, Luis M.
[Aims] To identify potential image biomarkers of neuromuscular disease by analysing morphological and network-derived features in skeletal muscle biopsies from a murine model of amyotrophic lateral sclerosis (ALS), the SOD1G93A mouse and wild-type (WT) controls at distinct stages of disease progression., [Methods] Using the NDICIA computational framework, we quantitatively evaluated histological differences between skeletal muscle biopsies from SOD1G93A and WT mice. The process involved the selection of a subset of features revealing these differences. A subset of discriminative features was selected to characterise these differences, and their temporal dynamics were assessed across disease stages., [Results] Our findings demonstrate that muscle pathology in the mutant model evolves from early alterations in muscle fibre arrangement, detectable at the presymptomatic stage through graph theory features, to the subsequent development of the typical morphological pattern of neurogenic atrophy at more advanced disease stages., [Conclusions] Our assay identifies a neurogenic signature in mutant muscle biopsies, even when the disease is phenotypically imperceptible., This work has been supported by the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CB18/05/00028, CIBERNED), by National Institute of Health Carlos III (ISCiii) of Spain through grants PI13/01347 (to L.M.E.) and PI23/01892 (to C.P.) and by Programme FORTALECE from the ISCiii through the grant FORT23/00008. P.G.-G. has been funded by Margarita Salas Fellowship – NextGenerationEU., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy

  • Piñol-Jurado, Patricia|||0000-0002-2757-5758
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Fernández Simón, Esther|||0000-0003-4804-6553
  • Gallardo, Eduard|||0000-0002-3942-3436
  • de la Oliva, Natalia|||0000-0002-1263-2705
  • Martínez-Muriana, Anna
  • Gómez-Gálvez, Pedro
  • Escudero, Luis M.
  • Pérez-Peiró, María|||0000-0001-9375-8416
  • Wollin, Lutz|||0000-0002-3617-5772
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
  • Illa, Isabel|||0000-0002-2186-2684
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
Duchenne muscle dystrophy (DMD) is a genetic disorder characterized by progressive skeletal muscle weakness. Dystrophin deficiency induces instability of the sarcolemma during muscle contraction that leads to muscle necrosis and replacement of muscle by fibro-adipose tissue. Several therapies have been developed to counteract the fibrotic process. We report the effects of nintedanib, a tyrosine kinase inhibitor, in the mdx murine model of DMD. Nintedanib reduced proliferation and migration of human fibroblasts in vitro and decreased the expression of fibrotic genes such as COL1A1, COL3A1, FN1, TGFB1, and PDGFA. We treated seven mdx mice with 60 mg/kg/day nintedanib for 1 month. Electrophysiological studies showed an increase in the amplitude of the motor action potentials and an improvement of the morphology of motor unit potentials in the animals treated. Histological studies demonstrated a significant reduction of the fibrotic areas present in the skeletal muscles. Analysis of mRNA expression from muscles of treated mice showed a reduction in Col1a1, Col3a1, Tgfb1, and Pdgfa. Western blot showed a reduction in the expression of collagen I in skeletal muscles. In conclusion, nintedanib reduced the fibrotic process in a murine model of dystrophinopathy after 1 month of treatment, suggesting its potential use as a therapeutic drug in DMD patients.